CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy
Journal of Controlled Release · 2025
DOI: 10.1016/j.jconrel.2025.114277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025. Verfasst von Shengnan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Suzhou Medical College of Soochow Unive…. Hauptthemen laut MEDLINE: Dendritic Cells, Myocardial Infarction, CD8-Positive T-Lymphocytes, CTLA-4 Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Priority Academic Program Development of Jiangsu Higher Education Institutions, National Key Research and Development Program of China, National Key Research and Development Program of China Stem Cell and Translational Research.
Abstract (Originalsprache)
Myocardial infarction (MI) remains a formidable global health challenge, as current therapies are hindered by excessive inflammation that exacerbates cardiac dysfunction and accelerates disease progression. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and CD28 are T-lymphocyte receptors with opposing roles in T-cell activation: CD28 binding to CD80/CD86 ligands on dendritic cells (DCs) mediates co-stimulation, whereas CTLA-4 engagement delivers inhibitory signals. In our present study, mannosylated cytotoxic T-lymphocyte antigen 4 (CTLA-4)-presenting small extracellular vesicles (CM@sEVs) were engineered for targeted MI therapy. By disrupting the CD80/86-CD28 costimulatory signaling, these CM@sEVs counteract dendritic cell (DC)-driven CD8+ T cell priming, thereby mitigating ischemic immunopathology while supporting myocardial repair. Notably, distinct from existing T-cell modulatory therapies, our CM@sEVs uniquely reshape in vivo T-cell dynamics directly through DC-dependent mechanisms, offering a precise and stable strategy for ischemic cardiomyopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Suzhou Medical College of Soochow University, Soochow University, Suzhou, China.
- Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Suzhou Medical College of Soochow University, Soochow University, Suzhou, China; School of Life Science, Tian…
- Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Suzhou Medical College of Soochow University, Soochow University, Suzhou, China; Department of Cardiovascular…
- State Key Laboratory for Innovation and Transformation of Luobing Theory, Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese…
- Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Suzhou Medical College of Soochow University, Soochow University, Suzhou, China. Electronic address: uuzyshen…
- Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Suzhou Medical College of Soochow University, Soochow University, Suzhou, China. Electronic address: chenweiq…
Förderung
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- National Key Research and Development Program of China
- National Key Research and Development Program of China Stem Cell and Translational Research
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Li, M., Shen, H., Zhou, W., Sun, J., Tang, Q., Liu, H., Zhang, W., Shen, Z., & Chen, W. (2025). CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.114277
Vancouver
Wang S, Li M, Shen H, Zhou W, Sun J, Tang Q, et al. CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.114277
BibTeX
@article{Wang2025,
author = {Wang, Shengnan and Li, Mengting and Shen, Han and Zhou, Wenjing and Sun, Jiuyuan and Tang, Qingsong and Liu, Hongman and Zhang, Wencheng and Shen, Zhenya and Chen, Weiqian},
title = {CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy},
journal = {Journal of Controlled Release},
year = {2025},
doi = {10.1016/j.jconrel.2025.114277}
}
EUVIMED